 TORONTO, ON ACCESSWIRE March 2, 2021 Edesa Biotech, Inc. NASDAQ:EDSA, a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the closing of its previously announced underwritten public offering of 1,562,500 common shares of Edesa, at a price to the public of 6.40 per share, less underwriting discounts and commissions. The gross proceeds were 10.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Edesa. 